Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 23743288)

1.

Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.

Lorenz M, Evers A, Wagner M.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4011-8. doi: 10.1016/j.bmcl.2013.05.022. Epub 2013 May 16. Review.

2.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

Tzefos M, Harris K, Brackett A.

Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Review.

PMID:
22232377
3.

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ.

Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Review.

PMID:
21208359
4.
5.

GLP-1R agonist therapy for diabetes: benefits and potential risks.

Samson SL, Garber A.

Curr Opin Endocrinol Diabetes Obes. 2013 Apr;20(2):87-97. doi: 10.1097/MED.0b013e32835edb32. Review.

PMID:
23403741
6.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

7.

Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.

Iepsen EW, Torekov SS, Holst JJ.

Expert Opin Pharmacother. 2014 Dec;15(17):2487-500. doi: 10.1517/14656566.2014.965678. Epub 2014 Sep 26. Review. Erratum in: Expert Opin Pharmacother. 2015 Jan;16(1):147.

PMID:
25260877
8.

Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.

Blonde L, Montanya E.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:20-32. doi: 10.1111/j.1463-1326.2012.01575.x. Review.

PMID:
22405266
9.

GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.

Gallwitz B.

Handb Exp Pharmacol. 2011;(203):53-74. doi: 10.1007/978-3-642-17214-4_3. Review.

PMID:
21484567
10.
11.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
12.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
13.

The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.

Eckerle Mize DL, Salehi M.

Curr Diab Rep. 2013 Jun;13(3):307-18. doi: 10.1007/s11892-013-0377-9. Review.

PMID:
23479200
14.

[Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].

Camafort-Babkowski M.

Med Clin (Barc). 2013 Aug 17;141(4):167-74. doi: 10.1016/j.medcli.2012.11.016. Epub 2013 Jan 18. Review. Spanish.

PMID:
23332622
15.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
16.

Recent advances in incretin-based therapies.

Russell-Jones D, Gough S.

Clin Endocrinol (Oxf). 2012 Oct;77(4):489-99. doi: 10.1111/j.1365-2265.2012.04483.x. Review.

PMID:
22804841
17.

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.

Gallwitz B.

Drugs. 2011 Sep 10;71(13):1675-88. doi: 10.2165/11592810-000000000-00000. Review.

PMID:
21902291
18.

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.

Campbell RK, Cobble ME, Reid TS, Shomali ME.

J Fam Pract. 2010 Sep;59(9 Suppl 1):S10-9.

PMID:
20824235
19.

The future of incretin-based therapy: novel avenues--novel targets.

Ahrén B.

Diabetes Obes Metab. 2011 Oct;13 Suppl 1:158-66. doi: 10.1111/j.1463-1326.2011.01457.x. Review.

PMID:
21824270
20.

Incretin therapy and its effect on body weight in patients with diabetes.

Lind M.

Prim Care Diabetes. 2012 Oct;6(3):187-91. doi: 10.1016/j.pcd.2012.04.006. Epub 2012 May 19. Review.

PMID:
22613745
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk